DBV Technologies S.A. (DBVT:NASDAQ) closed at $9.05 on October 16, 2026, down 0.66% on the day. The stock trades 65.4% below its 52-week high of $26.19 and 4.9% above its 52-week low of $8.63. Over the past year, it lost 46.6%. DBV Technologies S.A. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -5.24% | -27.66% | -37.89% | -56.90% | -46.61% |
In 252 trading sessions since October 16, 2025, DBVT closed higher on 103 days (41%). Its best day was December 17, 2025 (+25.42%) and its worst was March 11, 2026 (-12.02%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 3 times.
DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.
Find more stocks like DBVT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.